SELECT SECTOR

PHARMA & LIFE SCIENCES: LATEST INTERVIEWS MORE INTERVIEWS

Arda Ural
PHD LIFE SCIENCES SECTOR LEADER, EY
"Heading to 2025, the outlook seems positive, particularly with US$1.3 trillion of capital available for dealmaking. This positions the industry to pursue external growth aggressively if internal pipelines fall short."
United States
Pharma & Life Sciences
Gil Roth
PRESIDENT, PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION (PBOA)
"Early-stage R&D projects face longer timelines, making them less attractive when inflation remains high. If interest rates continue to decline, there could be increased investment in earlier-stage assets."
United States
Pharma & Life Sciences
Gaurav Kaushik
MD AND CEO, METEORIC BIOPHARMACEUTICALS
"We have witnessed growing interest in utilizing plant-derived enzymes across various applications."
United States
Pharma & Life Sciences
Saurabh Gurnurkar
MANAGING DIRECTOR, UQUIFA GROUP
"We can now initiate projects in Budapest and conclude them at our larger-scale GMP facility in Spain and/or Mexico, offering to our customers an option for integrated project management for their programs."
United States
Pharma & Life Sciences

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

Ontario Mining and Toronto's Global Reach 2025

GBR’s Ontario Mining and Toronto’s Global Reach 2025 report draws from over 130 interviews with leading C-level executives from producers, juniors, contractors, financial institutions and service providers to provide an updated overview of the complex mining ecosystem and offer a glimpse into the future of one of Canada’s most essential sectors.
MORE PREVIOUSLY PUBLISHED

PARTNER EVENTS

SEE ALL